GKOS
GLAUKOS Corp
NYSE · Healthcare · Medical - Devices · US
$166.96
+1.29%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$164.71
From 52W high−11.92%
Volume723867.00
Market cap$9.85B
P/E (TTM)—
P/S (TTM)16.1x
Div yield—
Key dataOct 19, 2026
Open
$164.71
From 52W high
−11.92%
Volume
723867.00
Market cap
$9.85B
ValuationView details →
P/E (Fwd)
451.1x
EV/EBITDA
−68.5x
P/E (TTM)
—
RSI (14)
52.1
MomentumView details →
1D Return
+1.29%
YTD Return
+48.58%
SummaryUpdated Jun 1, 2026
Glaukos Corporation (NASDAQ:GKOS) is a specialized ophthalmic medical technology and pharmaceutical company founded in 1998 and headquartered in San Clemente, California. The company went public in June 2015 and has established itself as a pioneer in minimally invasive glaucoma surgery (MIGS) and innovative ocular therapeutics. Glaukos focuses on developing and commercializing novel therapies for treating glaucoma, corneal disorders, and retinal diseases, with a particular emphasis on what it calls "interventional glaucoma" - a proactive approach to treating eye pressure and preventing vision loss before significant damage occurs.
Similar companies
Latest newsMore news →
GLAUKOS Corp shares declined 6.3% following the licensing news.10d agoGLAUKOS Corp reported successful topline outcomes from its latest Phase 4 clinical study of a novel eye therapy, describing superior intraocular pressure reduction.10d agoGlaukos announced positive topline results from its Phase 4 GLK-101-04 trial evaluating iDose TR with cataract surgery versus cataract surgery alone in patients with open-angle glaucoma.11d ago